(Reuters) -Algen Biotechnologies said on Monday it had agreed to grant AstraZeneca a license to develop therapies the U.S.-based biotech discover using its AI-driven gene-editing platform, in a deal worth up to $555 million. AstraZeneca will get exclusive rights to develop and sell approved therapies, if any, that target immune system-related disorders in exchange for upfront and milestone payments to Algen. AstraZeneca has been advancing its cell and gene therapy capabilities through acquisitions and pa ...

Algen Biotechnologies said on Monday it has agreed to grant AstraZeneca a license to develop gene therapies the U.S.-based biotech discovers using its artificial intelligence-driven platform, in a dea... ...

Group 1 - AstraZeneca has signed a deal worth $555 million with Algen Biotechnologies, a biotech company based in San Francisco [1]

AstraZeneca and Daiichi's drug Datroway helped breast cancer patients with a particularly hard to treat form of the disease live longer https://t.co/3A1mbqzvtu ...

AstraZeneca said on Monday its precision drug Datroway improved overall survival and progression free survival in patients with an advanced form of breast cancer versus chemotherapy in a trial when given early during treatment. ...

Company Performance - Astrazeneca's stock closed at $85.31, reflecting a +1.98% change from the previous day's closing price, outperforming the S&P 500 which gained 0.01% [1] - Over the past month, Astrazeneca shares have increased by 2.29%, which is below the Medical sector's gain of 4.67% and the S&P 500's gain of 4.83% [1] Earnings Projections - The upcoming EPS for Astrazeneca is projected at $1.14, indicating a 9.62% increase compared to the same quarter of the previous year [2] - Revenue is expected to reach $14.86 billion, representing a 9.57% increase compared to the same quarter of the previous year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $4.58 per share and revenue at $58.6 billion, reflecting changes of +11.44% and +8.37% respectively from the previous year [3] - Recent changes to analyst estimates suggest a positive outlook for Astrazeneca's business trends [3] Valuation Metrics - Astrazeneca has a Forward P/E ratio of 18.26, which is lower than the industry average of 19.42 [6] - The company has a PEG ratio of 1.54, compared to the industry average PEG ratio of 1.82 [6] Industry Ranking - The Medical - Biomedical and Genetics industry, which includes Astrazeneca, has a Zacks Industry Rank of 74, placing it in the top 30% of over 250 industries [7] - The top 50% rated industries are shown to outperform the bottom half by a factor of 2 to 1 [7]

I wrote back in January that I believed the drug stocks would outperform the general stock market for the first time in years in 2025 . The rationale was quite simple-valuations were conservative yetAnalyst’s Disclosure:I/we have a beneficial long position in the shares of LLY, AZN, NVO, PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business re ...

Key Points AstraZeneca's shares jumped after Pfizer's announcement of a major deal with the Trump administration. Pfizer's good news could benefit AstraZeneca, too. 10 stocks we like better than AstraZeneca Plc › Shares of AstraZeneca (NASDAQ: AZN) have jumped more than 10% this week. On Monday, the British drugmaker reported positive results from a clinical study of Enhertu in treating HER2-positive early breast cancer. However, the main reason for AstraZeneca's big gain was Pfizer's (NYSE: PFE) a ...

We recently published 10 Stocks Stealing The Spotlight Today. AstraZeneca PLC (NASDAQ:AZN) is one of the top performers on Wednesday. AstraZeneca saw its share prices jump to a new all-time high on Wednesday, as investors cheered reports that President Donald Trump delayed the imposition of a 100-percent tariff on all pharmaceutical imports. A report by Politico quoting a White House official said that Trump delayed the imposition of drug levies, set to take effect today, October 1, as the US government ...

Ah, the stock market. That bastion of rational expectations, predictable trends, and calm, measured responses to geopolitical shifts. Or, if you’ve been paying attention to the past few years, a wild, unpredictable beast often dancing to the tune of a single, very loud, and frequently contradictory, trumpet. President Donald Trump, a man whose policy announcements often arrive via social media, has once again graced the financial world with a fresh batch of pronouncements, leading to the usual cocktail of r ...